HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

SIMPLE SUMMARY: Treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs)—cetuximab and panitumumab—produced clinical benefits in a subset of patients with metastatic colorectal cancer (mCRC). Here, the authors investigated the relative expression and predictive value...

Descripción completa

Detalles Bibliográficos
Autores principales: Khelwatty, Said A., Puvanenthiran, Soozana, Essapen, Sharadah, Bagwan, Izhar, Seddon, Alan M., Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914886/
https://www.ncbi.nlm.nih.gov/pubmed/33562755
http://dx.doi.org/10.3390/cancers13040638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914886/
https://www.ncbi.nlm.nih.gov/pubmed/33562755
http://dx.doi.org/10.3390/cancers13040638

Ejemplares similares